Neurotrope Inc. (NTRP) is currently testing bryostatin-1 (bryostatin) in patients with moderate to advanced Alzheimer's disease ((AD)) patients (MMSE scores of 4-15). Considering that neurodegeneration begins decades before symptoms appear, these patients are the hardest to improve. Neurotrope is currently running a confirmatory phase 2 trial of bryostatin. This article analyses the relevant research findings to indicate the probability of bryostatin's efficacy and, thus, Neurotrope's value.
An initial phase 2 result showed that the 20 ug bryostatin group improved on the Severe Impairment Battery (SIB) test compared to the placebo group (1-tailed test, p =